United States - English - NLM (National Library of Medicine)

lexicon pharmaceuticals, inc. - telotristat ethyl (unii: 8g388563m7) (telotristat - unii:381v4fcv2z) - telotristat ethyl 250 mg - xermelo is indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy. none. risk summary there are no human data with xermelo use in pregnant women to inform a drug-associated risk. in animal reproduction studies, no effects on embryo-fetal development were observed with the administration of oral telotristat ethyl to rats during organogenesis at doses up to 750 mg/kg/day (approximately 9 times the exposure at the rhd [recommended human dose]). treatment of pregnant rabbits with oral telotristat ethyl during organogenesis produced maternal toxicity and post-implantation loss at doses of 250 mg/kg/day or higher (approximately 15 times the exposure at the rhd), and reduced fetal weight at 500 mg/kg/day (approximately 33 times the exposure at the rhd). in a pre-/postnatal development study, an increased incidence of mortality in rat offspring was observed during postnatal days 0 to 4 at the maternal oral do

European Union - English - EMA (European Medicines Agency)

serb sas - telotristat etiprate - carcinoid tumor; neuroendocrine tumors - other alimentary tract and metabolism products - xermelo is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (ssa) therapy in adults inadequately controlled by ssa therapy.

Israel - English - Ministry of Health

medison pharma ltd - telotristat ethyl as etiprate - film coated tablets - telotristat ethyl as etiprate 250 mg - xermelo is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (ssa) therapy in adults inadequately controlled by ssa therapy.

Canada - English - Health Canada

serb sas - telotristat ethyl (telotristat etiprate) - tablet - 250mg - telotristat ethyl (telotristat etiprate) 250mg - antidiarrhea agents

Australia - English - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - telotristat etiprate, quantity: 327.9 mg (equivalent: telotristat ethyl, qty 250 mg) - tablet, film coated - excipient ingredients: hyprolose; colloidal anhydrous silica; lactose; magnesium stearate; croscarmellose sodium; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - xermelo is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy.

United States - English - NLM (National Library of Medicine)

seroyal usa - gelsemium sempervirens root (unii: 639kr60q1q) (gelsemium sempervirens root - unii:639kr60q1q) - gelsemium sempervirens root 3 [hp_x] - indications for the temporary relief of flu symptoms, fever, sore throat indications for the temporary relief of flu symptoms, fever, sore throat directions adults: take five granules three times daily or as recommended by your healthcare practitioner. children: take three granules and follow adult directions.

United States - English - NLM (National Library of Medicine)

standard homeopathic company - gelsemium sempervirens root (unii: 639kr60q1q) (gelsemium sempervirens root - unii:639kr60q1q) - gelsemium sempervirens root 30 [hp_x] in 1 g - dull headache or flu

United States - English - NLM (National Library of Medicine)

uriel pharmacy inc - gelsemium sempervirens root (unii: 639kr60q1q) (gelsemium sempervirens root - unii:639kr60q1q), bryonia cretica subsp. dioica root (unii: 53ub5fh7cx) (bryonia cretica subsp. dioica root - unii:53ub5fh7cx) - gelsemium sempervirens root 3 [hp_x] - directions: for oral use only. use: temporary relief of flu symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - elotuzumab, quantity: 440 mg - injection, powder for - excipient ingredients: sodium citrate dihydrate; citric acid monohydrate; sucrose; polysorbate 80; water for injections - empliciti (elotuzumab) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - elotuzumab, quantity: 340 mg - injection, powder for - excipient ingredients: sodium citrate dihydrate; citric acid monohydrate; sucrose; polysorbate 80; water for injections - empliciti (elotuzumab) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.